- Catheter Precision (VTAK, Financial) to present four abstracts at the Heart Rhythm Society (HRS) 2025 meeting.
- VIVO system shows 94% accuracy and 83% long-term success in European study.
- LockeT device study confirms safety and effectiveness in large-bore access procedures.
Catheter Precision, Inc. (VTAK), a leading innovator in medical device technology for cardiac electrophysiology, has announced its participation in the 46th annual Heart Rhythm Society (HRS) meeting, scheduled from April 24 to 27, 2025, in San Diego, California. This prominent conference is expected to gather nearly 10,000 professionals in arrhythmia care and electrophysiology, featuring more than 200 educational sessions and over 3,400 scientific abstracts.
During the event, Catheter Precision will present four research abstracts, focusing on its VIVO system and LockeT device. The VIVO system, a non-invasive 3D imaging technology, demonstrated a 94% accuracy rate in a European multi-center study involving 125 patients, with long-term procedural success exceeding 83%. Notably, VIVO also achieved 89% accuracy in predicting exit site locations for scar-dependent ventricular tachycardia (VT), with 86% of patients remaining free from device therapy after one year.
Additionally, the LockeT device was highlighted for its safety and efficacy in large-bore access electrophysiological procedures. Involving 139 patients, the study showcased LockeT's capability in creating hemostasis during ablation procedures, particularly for cases involving large bore puncture sites for devices like the Boston Scientific Watchman and Medtronic Micra pacemaker.
The HRS 2025 meeting serves as a global platform for showcasing advancements in patient care through the latest research and innovation in electrophysiology, underlining Catheter Precision's commitment to advancing cardiac arrhythmia treatment solutions.
